Genome-wide transcriptome study using deep RNA sequencing for myocardial infarction and coronary artery calcification by Zhang, X. (Xiaoling) et al.
Zhang et al. BMC Med Genomics           (2021) 14:45  
https://doi.org/10.1186/s12920-020-00838-2
RESEARCH ARTICLE
Genome-wide transcriptome study using 
deep RNA sequencing for myocardial infarction 
and coronary artery calcification
Xiaoling Zhang1,2,3,4* , Jeroen G. J. van Rooij5, Yoshiyuki Wakabayashi6, Shih‑Jen Hwang1,2, 
Yanqin Yang6, Mohsen Ghanbari5, Daniel Bos7,8, BIOS Consortium, Daniel Levy1,2, Andrew D. Johnson1,2, 
Joyce B. J. van Meurs5, Maryam Kavousi5, Jun Zhu6 and Christopher J. O’Donnell1,2,9*
Abstract 
Background: Coronary artery calcification (CAC) is a noninvasive measure of coronary atherosclerosis, the proximal 
pathophysiology underlying most cases of myocardial infarction (MI). We sought to identify expression signatures of 
early MI and subclinical atherosclerosis in the Framingham Heart Study (FHS). In this study, we conducted paired‑end 
RNA sequencing on whole blood collected from 198 FHS participants (55 with a history of early MI, 72 with high CAC 
without prior MI, and 71 controls free of elevated CAC levels or history of MI). We applied DESeq2 to identify coding‑
genes and long intergenic noncoding RNAs (lincRNAs) differentially expressed in MI and high CAC, respectively, 
compared with the control.
Results: On average, 150 million paired‑end reads were obtained for each sample. At the false discovery rate (FDR) 
< 0.1, we found 68 coding genes and 2 lincRNAs that were differentially expressed in early MI versus controls. Among 
them, 60 coding genes were detectable and thus tested in an independent RNA‑Seq data of 807 individuals from the 
Rotterdam Study, and 8 genes were supported by p value and direction of the effect. Immune response, lipid meta‑
bolic process, and interferon regulatory factor were enriched in these 68 genes. By contrast, only 3 coding genes and 
1 lincRNA were differentially expressed in high CAC versus controls. APOD, encoding a component of high‑density 
lipoprotein, was significantly downregulated in both early MI (FDR = 0.007) and high CAC (FDR = 0.01) compared with 
controls.
Conclusions: We identified transcriptomic signatures of early MI that include differentially expressed protein‑coding 
genes and lincRNAs, suggesting important roles for protein‑coding genes and lincRNAs in the pathogenesis of MI.
Keywords: Gene expression signatures, Protein‑coding gene, Long intergenic non‑coding RNA, Myocardial 
infarction, Coronary artery calcification, Whole blood, RNA‑Seq
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Highlights
• More than 25% long intergenic noncoding RNAs 
(lincRNAs) are detectable whole blood via deep 
RNA Sequencing with 150 million paired-end reads 
obtained for each sample on average.
• 68 protein-coding genes and 2 lincRNAs that were 
differentially expressed in early myocardial infarction 
(MI) cases versus controls.
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• Immune response, lipid metabolic process, and inter-
feron regulatory factor were enriched in these 68 
protein-coding genes.
• Alternatively, only 3 coding genes and 1 lincRNA 
were differentially expressed in high coronary artery 
calcification (CAC) cases versus controls.
• APOD, encoding a component of high density lipo-
protein, was significantly downregulated in both 
early MI and high CAC compared with the control 
group after adjusting for sex and 9 clinical vascular-
related covariates, suggesting a potential novel target 
for the treatment and prevention of atherosclerotic 
disease.
Background
Myocardial infarction (MI) is a leading cause of death 
in men and women worldwide [1, 2] Genetic inherit-
ance is a major component to MI risk, particularly for 
early onset MI [1]. Coronary artery calcification (CAC) is 
directly correlated with quantity of coronary atheroscle-
rotic plaque [3]. CAC detected by computed tomography 
is a noninvasive measure of coronary atherosclerosis and 
a CAC score is a strong independent predictor of future 
MI [4] including early MI [5, 6]. Genome-wide associa-
tion studies (GWAS) have identified common and rare 
genetic variants associated with both CAC and early MI, 
including variants in the 9p21, SORT1 and PHACTR1 loci 
[7–11]. However, the molecular mechanisms underlying 
early MI and CAC remain unclear. In particular, data are 
sparse regarding gene expression signatures for early MI 
and for subclinical coronary atherosclerosis, detected as 
high CAC.
RNA sequencing for atherothrombotic cardiovascular 
disease offers a complementary genome-wide molecu-
lar approach to investigate disease-related mechanisms 
by measuring expression abundance of protein-coding 
genes (mRNA) and long intergenic non-coding genes 
(lincRNAs) in specific tissues. Altered expression levels 
in disease can reflect the effects of genetic variation, envi-
ronmental effects, interaction between genetic variation 
and environmental effects, and the effects of the disease 
process itself or drugs used for its treatment. We con-
ducted deep paired-end RNA sequencing (RNA-Seq) on 
whole blood samples collected from Framingham Heart 
Study (FHS) participants. Blood is an easily accessible 
tissue relevant for expression profiling of cardiovascular 
disease and its risk factors, has the advantage of provid-
ing information on patients’ real-life state in contrast 
with cell-lines, and can be extended to very large sample 
sizes for biomarker screening.
Our current study aimed to generate and character-
ize coding and noncoding gene expression signatures 
of early-onset MI and CAC in whole blood collected 
from a single large cohort, the Framingham Heart 
Study (FHS), and to further examine the relationships 
between high CAC and early-onset MI based on expres-
sion profiling of whole blood. We studied 198 Euro-
pean ancestry individuals (55 with history of early MI, 
72 with high CAC without MI, and 71 control partici-
pants free of elevated CAC levels or history of MI) with 
whole-blood RNA-Seq. To the best of our knowledge, 
this is a first whole-transcriptome study using RNA-Seq 
in participants with a history of prior MI or coronary 
atherosclerosis detected by the presence of CAC in a 
single study sample. We first performed a genome-wide 
transcriptome screen to identify blood-specific tran-
scripts including mRNA and lincRNAs. Second, we 
conducted association analyses between MI/CAC and 
the expression levels of individual mRNAs and of lin-
cRNAs. Last, we categorized the functional pathways 
of differentially expressed genes (DEGs) between MI/
CAC and controls to identify biological functions of 
the differentially expressed genes. Using deep cover-
age RNA-Seq data, we identified 12,062 protein-coding 
genes and 3707 lincRNAs expressed at relatively high 
levels in blood as well as significant MI-specific expres-
sion signatures, with eight genes (15%) supported in 
an independent cohort with RNA-Seq data. We sought 
to provide insights into mechanisms through which 
transcriptome-level variation may influence the devel-
opment of subclinical coronary atherosclerosis and, 
ultimately, clinical MI.
Methods
Study population and sample collection
The FHS started in 1948 with 5209 randomly ascer-
tained participants from Framingham, MA, who under-
went biennial examinations to investigate cardiovascular 
disease and its risk factors [12]. In 1971, the Offspring 
cohort [13, 14] (comprised of 5124 children of the orig-
inal cohort and the children’s spouses) and in 2002, the 
Third Generation (consisting of 4095 children of the Off-
spring cohort), were recruited [15]. Participants of the 
Framingham Heart Study (FHS) Offspring cohort who 
attended examination 8 (n = 202, 57 with early MI, 74 
with high CAC without MI, and 71 control participants 
free of elevated CAC levels and MI matched with age and 
sex) were included, constituting a total of 198 individu-
als. The clinical characteristics of the FHS Offspring par-
ticipants included in this study are presented in Table 1, 
and they are European ancestry. The study protocol was 
reviewed by the Boston University Medical Center Insti-
tutional Review Board, and all participants gave written 
informed consent.
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RNA library preparation, sequencing, and data processing
Fasting peripheral whole blood samples (2.5 ml) were 
collected in PAXgene™ tubes (PreAnalytiX, Hombrech-
tikon, Switzerland), incubated at room temperature for 
4 h for RNA stabilization, and then stored at − 80 °C. 
Total RNA was isolated from frozen PAXgene blood 
tubes by Asuragen, Inc., according to the company’s 
standard operating procedures for automated isolation 
of RNA from 96 samples in a single batch on a King-
Fisher® 96 robot. RNA was extracted; most globin RNA 
was removed (GLOBINclear Kits, Life Technologies, 
and Grand Island, NY, USA). 10 ng of total RNA was 
used as input for RNA-Seq library construction using 
Ovation RNAseq v2 (NuGEN Technologies, Inc., San 
Carlos, CA), following the guidelines for the Ovation 
SP Ultralow Multiplex System (NuGEN Technologies, 
Inc., San Carlos, CA). After the final amplification step, 
libraries were size selected between 250 to 450 base 
pairs. Library quality was verified for each sample using 
MiSeq (Illumina, Inc., San Diego, CA), sequencing with 
75-bp paired-end reads. Sequencing data production 
was carried out with Illumina HiSeq 2000 (Illumina, 
Inc.; 75-bp pair-ended reads, 1 library/sample per lane) 
for 202 individuals, yielding 150 million paired-end 
reads (average) per individual. Reads were mapped to 
the NCBI v37 Homo sapiens reference genome using 
Tophat. Complete RNA-seq data are available in dbGaP 
(see data access note below). Details of RNA isolation, 
preparation of cDNA from RNA, and RNA-sequencing 
and data processing are available in the Additional 
file 1: Supplemental Material.
Data quality of raw sequencing data (.fastq) for each 
sample is assessed using FASTQC, and 75 bp paired-
reads are aligned to the human reference genome 
sequence (hg19) using Bowtie2 within Tophat2 [16]. 
Samples with a low overall mapping rate (less than 50%) 
are defined as outliers and excluded from downstream 
analysis. We also sequenced 9 samples twice. For sam-
ples sequenced twice, the sample with higher number of 
sequenced reads and unique mapping rate was retained 
in the analysis. After assessment of quality based on map-
ping rate, sex mismatch checking using gene markers on 
chromosome Y, and outlier detection by principle com-
ponent analysis (PCA), a total of 198 samples remained 
for use in all downstream analysis of this study. The flow-
chart of this analysis pipeline is shown in Fig. 1.
Characterization of coding genes and non‑coding lincRNAs 
that are specifically expressed in blood using deep 
RNA‑Seq
After alignment, using an annotation file (Ensembl) 
[17], fragments per kilobase of transcript per million 
mapped reads (FPKM) values are derived using Cuf-
flinks [18] to be used as expression measurements for 
each feature (22,881 protein-coding genes and 7364 
lincRNAs). For Illumina BodyMap RNA-seq data 
which contains 16 human tissues, the raw .fastq files 
were downloaded and processed as described above 
Table 1 Clinical characteristics of the FHS Offspring participants included in this study (N = 198) at examination 8
MI Myocardial infarction, CAC Coronary artery calcification, BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, TC Total cholesterol, 
TC_HDL TC/HDL, HDL High-density lipoprotein cholesterol, Rx drug therapy
N = 198 Early MI
(n = 55)





Age (years) 68.47 ± 7.80 67.73 ± 9.19 67.46 ± 5.78 0.76
Sex 42 M, 13F 30 M, 42F 36 M, 35F 0.00037
BMI (kg/m2) 29.07 ± 4.72 29.39 ± 5.60 28.99 ± 5.46 0.937
SBP (mmHg) 125.3 ± 17.62 132 ± 17.01 127.3 ± 15.06 0.064
DBP (mmHg) 69.02 ± 9.24 73.58 ± 10.49 74.49 ± 8.71 0.0041
TC (mg/dl) 154.7 ± 33.79 179.9 ± 34.22 183.2 ± 31.97 4.49E‑06
TC_HDL 3.38 ± 1.12 3.62 ± 1.15 3.42 ± 0.97 0.41
Triglycerides (mg/dl) 126.4 ± 82.09 138.1 ± 87.1 114.4 ± 53.14 0.17
HDL (mg/dl) 48.69 + 14.53 53.06 + 13.94 57.58 (18.83) 0.009
Fasting glucose (mg/dl) 111.2 ± 30.76 112.5 ± 26.63 105 ± 14.85 0.16
Hypertension Rx (%) 54 47 37 1.02E‑07
Diabetes Rx (%) 13 18 7 0.042
Lipid Rx (%) 51 46 32 1.78E‑07
Cigarette use (current) (%) 9 5 2 0.02
Aspirin Rx (%) 44 43 31 0.0002
Diabetes mellitus (%) 11 15 9 0.04
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to obtain FPKM values for each transcript. After nor-
malizing data and removing batch effects [19], a linear 
regression model is applied to identify coding genes 
and lincRNAs that are expressed at a higher level in 
blood than in 16 other tissues in the BodyMap. Can-
didate genes are viewed in IGV [20, 21]. Expression 
measurements for coding-genes and lincRNAs were 
quantified by using Cufflinks as reported recently [22, 
23].
Estimation of hidden confounders and their association 
with known clinical phenotypes and technical variables
Besides known batch effects (sequencing batch) and 
known covariates, in order to take into account known 
and unknown technical effects, and other unwanted vari-
ations (e.g., proportions/frequencies of the various cell 
types present in whole blood) in the analysis, we applied 
the Surrogate Variable Analysis (SVA) [24] to calculate 
hidden variables, but in the meanwhile preserving bio-
logical heterogeneity in high-throughput experiments. 
These computed hidden variations are needed to be 
adjusted in the downstream analysis model to decrease 
false positives.
FPKM values of all transcripts estimated (including 
coding genes, lincRNAs, antisense transcripts, pseudo-
genes, etc) were used as the input for SVA package to 
estimate the surrogate variable (SV). Two significant SVs 
were finally selected and included in the downstream 
association analysis.
Identification of coding‑gene and lincRNA expression 
signatures associated with MI and CAC 
For our differential expression analysis, we first filtered 
for stably expressed mRNAs and lincRNAs in whole 
blood (FPKM > 0.1 in > = 10% of samples). After filter-
ing non-expressed genes, for each of 12,062 protein-
coding genes and 3707 lincRNAs, we applied DESeq2 
[25] to identify genes differentially expressed in MI 
and high CAC, respectively, compared with the control 
group. Since sex are statistically different among early 
MI, high CAC and control (P = 0.00037), we adjusted for 
sex besides known batch effects and hidden confounders 
(i.e. 2 SVs estimated from the above step) in the model 
in which the raw count is the outcome (dependent vari-
able), disease status (MI/CAC/control) is the predictor, 
and age, known batch effects and hidden confounders 
were included as covariates. Since these 198 participants 
were selected from un-related families, no family struc-
ture was adjusted for in the model. We applied the pack-
age DESeq2 in R to estimate the disease effects.
Protein‑coding gene expression association analysis
A total of 12,062 tests were performed examining the 
associations between each of the expressed coding-genes 
and MI and high CAC, respectively, compared with the 
control group. Following a Bonferroni multiple test cor-
rection (Benjamini and Hochberg method), a false dis-
covery rate (FDR) < 0.1 (corresponding to a nominal P 
value of 5.61E-4) was used to define significant asso-
ciations between the expression level of code-genes and 
the disease status (differentially expressed coding genes 
with MI and high CAC, respectively). In addition, for 
genes differentially expressed between MI and control at 
FDR < 0.1, we performed a secondary, hypothesis-gener-
ating analysis to test expression level changes between 
MI and high CAC.
LincRNA expression association analysis
A total of 3707 tests were performed examining the 
associations between each of the expressed lincRNAs 
and MI and high CAC, respectively, compared with the 
control group. The same significance level of FDR < 0.1 
(corresponding to a nominal P value of 6.33E-05) was 
used to define significant associations between the lin-
cRNA expression level and the disease status (differen-
tially expressed coding genes with MI and high CAC, 
respectively).
Gene ontology enrichment analysis to examine biological 
functions of gene signatures
For the 435 coding genes expressed moderately and 
highly in blood, we submitted their unique gene symbol 
to the DAVID website [26, 27] to identify GO molecular 
Fig. 1 Flowchart of sequencing mapping, quantification and 
expression analysis of RNA‑Seq data to identify coding and 
non‑coding expression signatures associated with MI and CAC 
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function categories, KEGG pathways, and CGAP Bio-
Carta Pathways over-represented among the 435 coding 
genes compared to background (all human genes). We 
accounted for multiple testing using Bonferroni-cor-
rected significance levels: 0.05/1472 = 0.00003 (cellular 
component) or 0.05/8972 = 0.000006 (biological process). 
The same analysis was conducted for the 68 coding genes 
differentially expressed between MI and control partici-
pants (FDR < 0.1).
Gene set enrichment analysis (GSEA)
The Molecular Signatures Database (MSigDB) is a collec-
tion of annotated gene sets for use with GSEA software 
[28]. Gene sets from the MSigDB were used to search 
for pathways that may be more modestly altered in MI-
associated gene expression data. A ranked gene list was 
generated by ranking t-value of 12,062 filtered genes in 
differentially expressed gene analysis using DeSeq2 with 
RNA-Seq count data. Then a total of 3283 gene sets in 
GSEA C2 category [28] (MSigDB) were used for the 
enrichment analysis. FDR < 0.25 was used to define the 
significance of enrichment. Gene set size of < 15 and > 500 
were filtered out, resulting in filtering out 1442/4725 
gene sets. Therefore, the remaining 3283 gene sets were 
used in the analysis.
Comparison of RNA‑Seq and exon array platform 
and validation of MI gene signatures detected from deep 
RNA‑Seq data using Affymetrix exon array data
In a sample of 198 samples with high quality RNA-Seq 
data being used in the analysis of this study, 193 RNA 
samples were also analyzed by Affymetrix Exon-array 
to obtain gene-level measurements. In order to be com-
parable between these two platforms, We first created a 
custom BED file based on the coordinates of core probe 
sets on exon-arrays so that only reads mapping to core-
probe sets are used by RSeQC [29] to obtain gene-level 
RPKM values. We found that the overall correlation of 
coding genes between RNA-Seq and Exon-array is only 
a little lower (r^2 = 0.56, Pearson correlation coefficient 
r = 0.75) than a previous study (r^2 = 0.62) [30], indicating 
the high quality of RNA-Seq human blood data consider-
ing that the previous study [30] was conducted in cell line 
samples.
We have identified 68 coding genes differentially 
expressed between 55 early MI and 71 control partici-
pants in whole blood, and then these genes were clas-
sified as MI genes. In order to estimate the relationship 
of the MI genes between RNA-Seq data in this study 
and Exon array data obtained before, MI genes were 
mapped to Exon array dataset via gene symbol. PCAs 
were performed for each dataset across the mapped 
genes using z-score normalized data. The relationship 
was subsequently defined quantitatively using GSEA. The 
samples in each dataset were divided into two groups: 
case versus control (MI vs. control). Then all of the genes 
in Exon array dataset were ranked by the signal to noise 
statistic (t value) in the MI case: control comparison. 
GSEA was used to determine if the gene set (MI-asso-
ciated genes) detected from deep RNA-Seq data were 
significantly enriched in the above ranked gene list gen-
erated from Exon array data.
Replication of MI expression signatures using IlIumina 
RNA‑Seq in an independent Rotterdam cohort
Rotterdam Study RNA-Seq data was generated as part 
of the BIOS project and is described in detail else-
where [31]. In short, total RNA was globin cleared using 
Ambion GLOBINclear and sequenced to a minimum 
yield of 15 M paired-end reads on HiSeq 2000. Data 
was aligned to reference genome hg19 using STAR, fol-
lowed by quantification of all GENCODE v16 genes using 
custom scripts. We then extracted the counts of 56,515 
transcripts for 807 participants of the Rotterdam Study 
(RS-I, II and III). Using edgeR, counts per million (CPM) 
mapped reads were generated for each sample, and tran-
scripts with CPM < 1 in more than 90% of samples were 
excluded, allowing 15,331 transcripts in further analysis. 
In summary, among 404 individuals (15 from RS-I and 
389 from RS-II, 190 male and 214 female), there are 28 
MI cases vs. 376 controls and 41 CHD cases vs. 363 con-
trols for the differential expression analyses.
For each coded phenotype (MI/CHD), linear regression 
analysis was performed in R, correcting for age, gender, 
flow-cell and the number of sequenced reads. A custom 
linear regression script was used as the dataset was too 
large to be processed by edgeR or DESeq. The effect sizes 
and uncorrected p-values were reported for each of the 
candidate genes of the discovery analysis.
See Additional file 1: Supplemental Material for details 
of Rotterdam cohort and its measurement of CAC.
Results
Sample characteristics and RNA quality of the blood 
samples
Two hundred two FHS Offspring participants with 
a history of early MI, high CAC, or neither and with 
whole blood expression data were selected for this RNA 
sequencing study. After exclusion for poor quality and 
outliers of two participants with history of early MI and 
two participants with high CAC, 198 samples remained 
for inclusion in the analysis. Our final study sample 
with RNA-Seq of whole-blood RNA consisted of 198 
European ancestry individuals (55 with history of early 
MI, 72 with high CAC without MI, and 71 control par-
ticipants free of elevated CAC levels or history of MI). 
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Clinical characteristics of these study participants are 
presented in Table  1. Participant selection was targeted 
to match for age and sex across three groups. As shown 
in Table  1, there was no difference in age (mean = 68, 
P = 0.76), but there were differences in the distributions 
of sex (P = 0.00037) and several other clinical covariates 
across groups including diastolic blood pressure, total 
cholesterol, HDL-C, smoking, diabetes and treatments 
for hypertension, dyslipidemia, or diabetes as well as use 
of aspirin (P < 0.05).
We compared the RNA quality across the three groups. 
The concentration and yield of RNA were slightly dif-
ferent (P = 0.03) with a relatively higher concentration 
and yield in controls, respectively. However, as shown in 
Additional file 1: Table S1, there are no differences among 
groups for RNA quality score i.e., RNA integrity number 
(RIN), and 260/280 ratio.
Transcriptome profiling of coding and non‑coding genes 
in human whole blood
By sequencing one sample per lane using Illumina HiSeq 
platform, we generated high-quality and deep coverage 
RNA-Seq data for 201 blood samples besides nine rep-
licates. On average, there were 150 million paired-end 
75 bp reads for each sample. The overall unique mapping 
rate is 75% and the concordant pair alignment rate was 
62%. Sequencing summary and mapping statistics are 
shown in Additional file 1: Fig. S1. For the nine samples 
sequenced twice, we checked the correlation of all meas-
ured transcriptome in whole blood between samples 
sequenced twice, which ranged from 0.77 to 0.99 (Addi-
tional file 1: Table S2). After QC, in the final analysis, for 
samples sequenced twice, we selected the one with the 
higher number of total unique mapped reads. Samples 
were also checked for sex mismatch. After exclusion for 
poor quality RNA and outliers, 198 samples remained for 
inclusion in the analysis.
Of 22,881 Ensembl protein-coding genes, 56% 
(12,823/22,881) were detectable  (log2[FPKM] > 1 in > 10% 
of the samples, FPKM = fragments per kilobase of tran-
script per million mapped reads). For protein-coding 
genes expressed in all samples, we found 4133 genes 
with  log2[FPKM] > 1, and 435 genes with  log2[FPKM] > 4. 
Gene ontology analysis showed that categories of 
immune and defense response, leukocyte activation, cal-
cium binding, leukocyte migration and adhesion were 
enriched in the 435 genes expressed moderately and 
highly in blood (Additional file 1: Table S4). Using a cut-
off of  log2[FPKM] > 0.1, 25.6% (1886/7364) lincRNAs 
are detectable in > 10% of the samples. For lincRNAs 
expressed in all samples, we found only 36 lincRNAs 
with  log2[FPKM] > 1, and 2 with  log2 [FPKM] > 4.These 
findings are consistent with prior observations that the 
expression levels of lincRNAs are much lower than those 
of mRNAs [32]. All protein-coding genes expressed at 
> = 4  log2[FPKM] and all lincRNAs expressed at > = 1 
 log2[FPKM] in all samples are listed in Additional file 1: 
Tables  S3 and S5 in the online-only Data Supplement, 
respectively.
We further identified protein-coding genes and lin-
cRNAs that were more highly expressed in whole blood 
by comparing to expression in other tissues in the Illu-
mina Human Body Map RNA-Seq data. The Illumina 
Human BodyMap  2.0 data [33] includes RNA-Seq data 
for 16 other human tissues, and we processed the Illu-
mina Human BodyMap  2.0 data with the same tools 
and parameters as for our blood RNA-Seq data. In this 
comparison, ~ 60% of the detectable coding-genes were 
expressed much higher in our blood samples than in 16 
other human tissues. As shown in the heat map of 52 
genes highly expressed in blood  (log2[FPKM] > 6 in 100% 
samples) and 36 lincRNAs moderately expressed in blood 
 (log2[FPKM] > 1 in 100% samples), half of coding genes 
are expressed specifically in blood (Additional file 1: Fig. 
S2a), and two thirds of lincRNAs are expressed higher in 
blood compared to other 16 human tissues. By evaluat-
ing the expression profiles of 36 lincRNAs expressed 
highly in blood  (log2 [FPKM) > 1 in all samples), two 
clusters were identified as shown in Additional file 1: Fig. 
S2b. Among them, the expression level of 26 lincRNAs 
(top panel) is substantially higher in blood compared to 
16 other human tissues in the Human BodyMap data, 
including the FAM157A lincRNA, a known lincRNA 
known to be overexpressed in blood, that contains 14 
exons and has 2 transcripts (splice variants) as shown in 
the Ensembl Genome Browser [34].
Finally, we compared the overall expression profiling on 
Illumina RNA-Seq and Affymetrix Exon-array platforms 
in all 193 participants with samples with expression data 
from both platforms. The correlation of expression level 
between the two platforms is on average 0.745 with a 
median of 0.748, which is slighter lower (R^2 = 0.56) than 
a prior report with an  R^2 of 0.62 between RNA-Seq and 
Exon-array data for 5 cell line samples [30]. The correla-
tion result is high, with overall r = 0.75. Additional file 1: 
Fig. S3a shows the correlation plot for one sample, and 
Additional file 1: Fig. S3b shows the distribution of r val-
ues for all 193 samples.
Differential expression analysis to identify mRNA 
and lincRNA signatures for early MI and high CAC 
At a false discovery rate (FDR) < 0.1, we found 68 coding 
genes and two lincRNAs differentially expressed between 
early MI and controls (Table  2), with 21 genes overex-
pressed in MI cases and 49 down-regulated, including 
two lincRNAs. By contrast, only three coding genes and 
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Table 2 Top MI-associated genes (68 protein-coding and  2 lincRNAs) at  FDR < 0.1. Eight coding genes supported by p 




(28 MI cases, 41 CHD cases)





301 − 0.19 1.29E‑06 0.0075 0.63 Yes 0.51
DUS1L 17:80015381‑
80,023,763
902 0.41 1.97E‑06 0.0075 0.778 No 0.331
AFF3 2:100162322‑
100,759,201
1478 −0.44 2.12E‑06 0.0075 0.326 Yes 0.397
IRF7 11:612552‑615,999 1652 0.41 2.50E‑06 0.0075 0.286 Yes 0.378
IPO5 13:98605911‑
98,676,551
1866 −0.32 3.75E‑06 0.0090 0.0416 Yes 0.115
SH3PXD2A 10:105348284‑
105,615,301
927 −0.40 5.93E‑06 0.0119 0.248 Yes 0.0541
BACH2 6:90636247‑91,006,627 3905 −0.37 1.09E‑05 0.0188 0.48 Yes 0.586
PAX5 9:36833271‑37,034,103 1406 −0.41 1.67E‑05 0.0252 0.451 Yes 0.339
PHF6 X:133507282‑
133,562,820
704 −0.33 1.99E‑05 0.0267 0.523 Yes 0.837
FCRL2 1:157715522‑
157,746,922
868 −0.40 2.26E‑05 0.0272 0.482 Yes 0.37
VEZT 12:95611521‑
95,696,566
1024 −0.32 2.97E‑05 0.0301 0.674 Yes 0.896
TRIM46 1:155145872‑
155,157,447
159 0.39 3.52E‑05 0.0301 0.429 Yes 0.22
IFI6 1:27992571‑
27,998,729
1711 0.39 3.60E‑05 0.0301 0.0291 Yes 0.0658
RAD52 12:1021242‑1,099,219 1090 −0.30 3.75E‑05 0.0301 0.65 No 0.394
BLK 8:11351509‑11,422,113 562 −0.39 3.87E‑05 0.0301 0.168 Yes 0.125
HLA-F 6:29690551‑29,706,305 5562 0.27 3.99E‑05 0.0301 0.307 Yes 0.286
IFI27 14:94571181‑
94,583,033
170 0.32 4.54E‑05 0.0306 0.506 Yes 0.783
HNRNPR 1:23630263‑
23,670,829
2946 −0.26 4.56E‑05 0.0306 0.00712 Yes 0.0141
ZNF44 19:12335500‑
12,405,702
671 −0.30 5.16E‑05 0.0319 0.704 No 0.336
FCER2 19:7753643‑7,767,032 592 −0.38 5.29E‑05 0.0319 0.904 Yes 0.747
FRS2 12:69864128‑
69,973,562
1778 −0.26 5.88E‑05 0.0328 0.913 No 0.576
HBG1 11:5269312‑5,271,122 17,515 0.35 5.98E‑05 0.0328 0.0753 Yes 0.38
PRKDC 8:48685668‑48,872,743 9155 −0.22 6.59E‑05 0.0337 0.41 Yes 0.907
MS4A1 11:60223224‑
60,238,233
3170 −0.38 6.91E‑05 0.0337 0.217 Yes 0.163
FCRLA 1:161676761‑
161,684,142
562 −0.37 6.98E‑05 0.0337 0.187 Yes 0.112
ACADVL 17:7120443‑7,128,592 3648 0.26 8.06E‑05 0.0370 0.061 No 0.0195
CCDC141 2:179694483‑
179,914,813
703 −0.37 8.28E‑05 0.0370 0.398 Yes 0.884
HBG2 11:5274419‑
5,667,019
39,577 0.33 9.13E‑05 0.0393 0.0082 Yes 0.0885
SKIL 3:170075465‑
170,114,623
1570 −0.25 9.53E‑05 0.0396 0.42 No 0.493
GPT2 16:46918289‑
46,965,209
100 −0.32 0.00012109 0.0487 0.414 Yes 0.267
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1034 −0.34 0.00013802 0.0537 0.213 Yes 0.161
ZNF445 3:44481261‑44,519,162 2182 −0.22 0.00014638 0.0552 0.995 Yes 0.681
RASGRF1 15:79252288‑
79,383,115
84 −0.22 0.00017229 0.0630 NA NA
FIGNL1 7:50511830‑50,518,088 234 −0.35 0.00017999 0.0639 0.61 No 0.394
PRKX X:3522410‑3,631,649 2556 −0.25 0.00018916 0.0652 0.0114 Yes 0.123
CLNKa 4:10488018‑10,686,489 96 −0.29 0.00020296 0.0670 NA NA
DDX6 11:118620033‑
118,661,858
10,805 −0.18 0.0002167 0.0670 0.986 No 0.62
DESI2 1:244816236‑
244,872,335
945 −0.27 0.00021823 0.0670 0.24 Yes 0.564
NPDC1 9:139933921‑
139,940,655
146 0.34 0.00021874 0.0670 0.000883 Yes 0.00258
NXF1 11:62559594‑
62,573,774
7228 0.16 0.00022235 0.0670 0.864 Yes 0.973
RNF113A X:119004496‑
119,005,791
297 0.34 0.00025995 0.0737 NA NA
RARS 5:167913449‑
167,946,304
1359 −0.27 0.0002653 0.0737 0.496 Yes 0.401
RHOBTB2 8:22844929‑22,877,712 558 −0.34 0.0002664 0.0737 0.0741 Yes 0.0351
UGGT1 2:128848773‑
128,953,251
4889 −0.18 0.00026872 0.0737 0.176 Yes 0.31
ISG15 1:948802‑949,920 635 0.34 0.00028111 0.0752 0.382 Yes 0.635
TIPARP 3:156391023‑
156,424,559
938 −0.26 0.00028679 0.0752 0.434 Yes 0.789
KSR2 12:117890816‑
118,406,788
98 −0.15 0.00029511 0.0757 NA NA
ATP6V0D1 16:67471916‑
67,515,140
8907 0.20 0.00032105 0.0807 0.792 Yes 0.966
FBXO11 2:48016454‑48,132,932 1609 −0.23 0.00033474 0.0811 0.182 No 0.0272
ZNF274 19:58694395‑
58,724,928
840 −0.29 0.00033608 0.0811 0.668 No 0.196
MCOLN1 19:7587511‑7,598,895 1777 0.32 0.00034818 0.0823 0.321 Yes 0.494
DDX24 14:94517265‑
94,547,591
2085 −0.27 0.0003551 0.0824 0.0259 Yes 0.138
PEX26 22:18560688‑
18,613,905
1308 −0.26 0.00036948 0.0835 0.0651 Yes 0.025
TBC1D23 3:99979843‑
100,044,095
1794 −0.22 0.00037386 0.0835 0.756 No 0.399
WNT3 17:44839871‑
44,910,520
137 −0.24 0.00039387 0.0858 NA NA
RAB30 11:82684174‑
82,782,965
804 −0.31 0.00040083 0.0858 0.659 Yes 0.635
ODF3B 22:50968138‑
50,971,009
533 0.33 0.00040552 0.0858 0.36 Yes 0.265
CDK2AP2 11:67273967‑
67,276,120
771 0.32 0.00042475 0.0872 0.604 No 0.365
CDKN2D 19:10677137‑
10,679,735
4162 0.28 0.00043108 0.0872 0.0279 Yes 0.0662
SLC6A16 19:49792894‑
49,828,482
611 −0.32 0.00043371 0.0872 0.654 Yes 0.38
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one lincRNA (RP11-245 J9) were differentially expressed 
between high CAC and controls (Table  3). Notably, 
APOD, encoding a component of high-density lipopro-
tein, was expressed significantly lower in both early MI 
(FDR = 0.007) and in high CAC (FDR = 0.01) compared 
with controls, respectively, highlighting a novel candidate 
for both MI and subclinical atherosclerosis.
A supervised clustering analysis of the 69 expres-
sion signatures (68 MI and 3 CAC genes with 2 genes 
shared by both MI and CAC) shows significant expres-
sion changes across the three groups (Fig.  2a). Princi-
ple component analysis (PCA) of 68 MI gene signatures 
(Fig. 2b) also shows a separation pattern between MI and 
controls. In addition, for DEGs, particularly for APOD 
detected in both MI and high CAC, boxplots show a 
clear trend in early MI and high CAC relative to con-
trols (Fig.  2c). APOD is ranked as the top gene in both 
MI  (log2 fold change = − 0.2, FDR = 0.007) and high CAC 
(FDR = 0.01) gene signatures. Of note, APOD was mod-
erately expressed in blood with an average of FPKM of 
3.79 across all 198 samples.
To assess whether our findings may represent tran-
scriptomic signatures confounded by baseline clinical 
variables/covariates, established vascular risk factors, or 
of drug treatments for MI or its risk factors, we further 
adjusted for 9 covariates that differed among the three 
groups (see Table  1) in the primary simple differential 
analysis model in which we had adjusted for sex, known 
batch effects, and hidden confounders (i.e. two SVs). The 
9 clinical covariates include diastolic blood pressure, total 
cholesterol, HDL-cholesterol, cigarette smoking, diabe-
tes, and drug treatment for hypertension, dyslipidemia, 
or diabetes as well as use of aspirin. For all 70 MI genes 
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427 0.32 0.00044545 0.0881 0.0415 No 0.0489
IRF4 6:391738‑411,447 1629 −0.30 0.00046627 0.0907 0.206 Yes 0.47
S100PBP 1:33282367‑33,324,476 2679 −0.23 0.00048111 0.0913 0.918 No 0.843
GPR15 3:98250742‑98,251,960 181 0.28 0.00048423 0.0913 0.162 Yes 0.0226
DNAH7 2:196602426‑
196,933,536
151 −0.33 0.00051455 0.0939 NA NA
TCF20 22:42556018‑
42,739,622
4310 −0.21 0.00052057 0.0939 0.216 Yes 0.307
EIF2S3L 12:10658200‑
10,675,734
393 −0.27 0.00052155 0.0939 NA NA
PSMB6 17:4699438‑4,701,790 615 0.31 0.00056066 0.0995 0.406 No 0.245
LINC00452b 13:114586639‑
114,588,308
14 −1.33 1.44E‑05 0.0453 NA NA
RP11-481 J2.2b 16:58455229‑
58,496,374
10 −1.21 6.33E‑05 0.0997 NA NA
Significance of bold are those 8 coding genes replicated at p value
a Two genes (APOD, CLNK) are also associated with high CAC as shown in Table 3
b lincRNAs; FDR False Discovery Rate, Rep Replication, MI Myocardial Infarction, CHD Coronary Heart Disease, NA genes not found in the Replication Rotterdam Study 
cohort, Base Mean the average of reads mapped to this gene across all samples, Rep_MI_direction the effect direction (i.e., log2FoldChange direction) in our discovery 
cohort is the same as in the Replication cohort
Table 3 Top CAC-associated genes (3 protein-coding and 1 lincRNA) at FDR < 0.1
a Two genes are also associated with MI as shown in Table 2; blincRNAs; FDR False Discovery Rate
Gene Symbol locus Gene_biotype Base Mean log2Fold Change P.value FDR
APODa 3:195295572‑195,311,076 protein_coding 300.6917 −0.211 1.12E‑06 0.0135
CLNKa 4:10488018‑10,686,489 protein_coding 96.22257 −0.364 7.38E‑06 0.039
RASGEF1A 10:43689982‑43,762,367 protein_coding 208.1619 0.418 9.71E‑06 0.039
RP11-245 J9.5b 3:63993757‑63,994,368 lincRNA 435.893 −0.59136 4.94E‑05 0.091
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except for APOD and DUS1L, there was overall attenu-
ation of the significance for MI signatures, and asso-
ciations for 9 genes remained significant at FDR < 0.1 
(Additional file  1: Table  S6). APOD remained signifi-
cantly downregulated in both early MI (FDR = 0.003, 
beta/log2FC = − 0.23) and high CAC (FDR = 0.01, beta/
log2FC = − 0.21). We hypothesize that APOD may rep-
resent a novel target for the treatment and prevention of 
atherosclerotic disease.
Finally, for the 68 coding genes differentially expressed 
between MI and control at FDR < 0.1, our secondary 
analysis found four genes also differentially expressed 
between MI and high CAC at a Bonferroni corrected 
p-value ≤ 0.0007 (0.05/68). Their expression level was 
changed in the same direction across the three groups. 
Three genes (IRF7, HBG2, and HBG1) were up-regulated 
in MI compared to high CAC and controls, and one gene 
(PEX26) was down-regulated in MI compared to high 
CAC and controls.
Pathway enrichment analysis to identify biological 
function pathway signatures for early MI
To explore biological functions and pathways in which 
the gene signatures of MI might act, we found that anno-
tations of the 68 MI genes were highly enriched for a 
few GO categories including protein complex binding 
and phosphoprotein (FDR < 0.05), compare to all human 
genes as background.
Gene set enrichment analysis (GSEA) [28] was con-
ducted to explore for enrichment of gene sets for the 
up-regulated and down-regulated genes in participants 
with MI compared to controls. In a total of 3283 gene 
sets in GSEA C2 category [28] at FDR < 25% enrich-
ment level, 215 gene sets were significantly up-regu-
lated (out of 1938) and eight gene sets were significantly 
down-regulated (out of 1345). As shown in Table 4 for 
gene sets significantly enriched at FDR < 5%, all 36 gene 
sets were up-regulated in MI with a positive Normal-
ized Enrichment Score, including several interferon 
response pathways, insulin receptor recycling, known 
targets of transcription factor STAT3, and a gene set 
related to epigenetic regulation in which 17 genes 
were significantly silenced by methylation (p-value = 0, 
and FDR q-value = 0.02). The up-regulation of gene 
expression in the group with early MI compared to con-
trols (Additional file 1: Fig. S4) supports the hypothesis 
for an epigenetic role in MI pathogenesis.
Other interesting gene sets at significantly enriched 
FDR < 25% but FDR > 5% include sets for hypoxia, oxi-
dative phosphorylation, inflammatory response, obe-
sity and cholesterol biosynthesis (Additional file  1: 
Table S7), consistent with a number of pathophysiologi-
cal pathways previously implicated in coronary artery 
disease and MI. New knowledge regarding these regu-
latory changes may improve our ability to functionally 
characterize susceptibility variants associated with dis-
eases and related risk factors.
Validation of MI expression signatures using Affymetrix 
exon‑array expression data
Of 198 RNA-Seq samples, there was an overlap of 193 
with the previous 5626 Affymetrix Exon-array data. 
Using these 193 common samples, only one gene 
(CLDN8, beta = 0.16, p = 2.84e-06, FDR = 0.05) was dif-
ferentially expressed between MI and controls, a find-
ing that was validated in exon array data at FDR < 0.1. 
For 10,595 expressed genes found in both platforms, 
we first computed the statistic t value for each gene 
on each platform by comparing MI cases with con-
trols. We found a significant correlation of the t values 
between RNA-Seq and exon array (r = 0.21, P < 1e-324, 
Additional file 1: Fig. S5), which is consistent with pre-
vious reports [30].
The replication rate of expression signatures may be 
low when performing single gene comparisons between 
different platforms (e.g., RNA-Seq and exon array) [28] 
or across different high-throughput studies. Therefore, 
we conducted a GSEA analysis to validate whether the 
68 DEG considered as an entire gene set is significantly 
enriched using exon array MI cases versus controls. 
For the protein coding genes, 66 unique genes were 
found on the exon-array. 17,873 exon array genes were 
ranked by t value (from positive to negative) in the MI 
case:control comparison. The enrichment is significant 
(nominal p-value < 0.001) with Normalized Enrich-
ment Score = − 2.14 (Fig.  3), indicating overall down-
regulation in MI compared with the controls in exon 
array data, consistent with our findings from RNA-
Seq (47 of 68 down-regulated genes). Additional file 1: 
Fig. 2 MI and CAC expression signatures. a Heatmap of 198 samples showing substantial differential expression changes across three groups 
(Controls, early MI, and high CAC). b Principle component analysis (PCA) of 70 MI gene signatures (68 protein‑coding and 2 lincRNAs) shows a 
separation pattern between MI and controls. c Examples of the genes significantly associated with both MI and high CAC. The boxplot shows a low 
expression level in early MI and high CAC compared to controls for APOD and vice versa for RASGEF1A. d Boxplot of 2 lincRNAs that are moderately 
expressed in blood and associated with MI and CAC by RNA‑Seq
(See figure on next page.)
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Table S8 reports 35 leading edge genes among the set of 
68 genes. The leading-edge subset can be interpreted as 
the core group of genes that accounts for the gene set’s 
enrichment signal [28].
Independent replication of MI expression signatures using 
Illumina RNA‑Seq in the Rotterdam study cohort
We further replicated our MI gene signatures in an inde-
pendent cohort, the Rotterdam Cohort study (N = 807) in 
which Illumina RNA-Seq was conducted. Among our 70 
MI genes (68 coding and 2 lincRNAs), 60 coding genes 
were detectable (CPM > 1 in > 10% of samples) and there-
fore analyzed in the Rotterdam RNA-Seq dataset. We 
Table 4 Gene set enrichment analysis (GSEA) for  enrichment of  gene sets/pathways for  the  up-regulated and  down-
regulated genes in participants with MI compared to controls
A total of 3283 gene sets in GSEA C2 category [28] were tested. At FDR < 25% enrichment level, 215 gene sets were significantly up-regulated (out of 1938) and eight 
gene sets were significantly down-regulated (out of 1345)
NES Normalized enrichment score, NOM p-val Nominal p-value, FDR q-val False discovery rate q-value




BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX 17 0.834137 0 0
DAZARD_UV_RESPONSE_CLUSTER_G4 15 0.810541 0 0
BOWIE_RESPONSE_TO_TAMOXIFEN 18 0.800464 0 0
ZHANG_INTERFERON_RESPONSE 22 0.760159 0 5.99E‑04
BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS 30 0.730185 0 0.001917
ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP 20 0.724651 0 0.002397
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_DN 20 0.687019 0 0.009875
UROSEVIC_RESPONSE_TO_IMIQUIMOD 20 0.687635 0 0.011115
STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN 38 0.67526 0 0.012077
CHIBA_RESPONSE_TO_TSA_UP 29 0.677011 0 0.012327
DAZARD_UV_RESPONSE_CLUSTER_G24 15 0.680731 0.001965 0.012367
MOSERLE_IFNA_RESPONSE 29 0.670738 0 0.013561
EINAV_INTERFERON_SIGNATURE_IN_CANCER 26 0.662667 0 0.016484
GALE_APL_WITH_FLT3_MUTATED_DN 16 0.652891 0 0.019301
LIANG_SILENCED_BY_METHYLATION_2 32 0.654796 0 0.02017
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_QTL 15 0.653422 0.006276 0.020191
JOSEPH_RESPONSE_TO_SODIUM_BUTY RAT E_UP 26 0.645603 0 0.021225
REACTOME_TRANSFERRIN_ENDOCYTOSIS_AND_RECYCLING 19 0.646882 0 0.021409
RASHI_NFKB1_TARGETS 18 0.648308 0 0.021688
CAVARD_LIVER_CANCER_MALIGNANT_VS_BENIGN 16 0.639799 0.001927 0.024119
DAUER_STAT3_TARGETS_DN 46 0.63281 0 0.026719
HARRIS_BRAIN_CANCER_PROGENITORS 15 0.633145 0.00404 0.027771
KRASNOSELSKAYA_ILF3_TARGETS_UP 28 0.633243 0 0.029035
RADAEVA_RESPONSE_TO_IFNA1_UP 47 0.626684 0 0.030557
KIM_LRRC3B_TARGETS 28 0.626813 0 0.03178
SUH_COEXPRESSED_WITH_ID1_AND_ID2_UP 16 0.623882 0.005906 0.032143
NOJIMA_SFRP2_TARGETS_DN 18 0.621049 0.002024 0.034003
XU_HGF_TARGETS_INDUCED_BY_AKT1_6HR 16 0.60961 0.008065 0.039922
BROWNE_INTERFERON_RESPONSIVE_GENES 63 0.610055 0 0.040405
REACTOME_INTERFERON_ALPHA_BETA_SIGNALING 46 0.610758 0 0.040506
GRATIAS_RETINOBLASTOMA_16Q24 15 0.611119 0.00813 0.041194
KANG_CISPLATIN_RESISTANCE_UP 16 0.611884 0 0.041448
WELCH_GATA1_TARGETS 18 0.613601 0 0.042096
OUYANG_PROSTATE_CANCER_PROGRESSION_DN 16 0.612352 0.004008 0.042214
REACTOME_INSULIN_RECEPTOR_RECYCLING 17 0.601722 0 0.049199
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found a significant correlation of the effect size of MI 
between our discovery FHS RNA-Seq and Rotterdam 
replication RNA-Seq (Spearman.r = 0.53, P < 1.3e− 05). 
Specifically, among 60 genes tested, we found 9 genes 
were differentially expressed between MI cases (n = 28) 
and controls (n = 376) at P < 0.05 (Table  2), and 8 were 
expressed differently in the same direction as indicated in 
bold in Table 2. In addition, among 8 coding genes sup-
ported by p value and direction, two genes were also dif-
ferentially expressed between CHD cases and controls in 
the same direction (HNRNPR with P = 0.01, and NPDC1 
with P = 0.0026). Furthermore, among 60 genes tested, 
77% (46 genes) of the associations are in the same effect 
direction between MI and controls, indicating consist-
ency of effect, although a larger sample size is needed to 
replicate significant associations with MI.
Discussion
Although GWAS have identified many genetic variants 
associated with MI and subclinical coronary atheroscle-
rosis (e.g. high CAC), the totality of evidence suggests 
that many GWAS variants are located in non-coding 
genomic regions. Genes reported for these variants are 
based on their proximity to nearby genes and limited to 
annotated protein-coding genes that may not represent 
the causal genes responsible for the traits studied, and 
much of the functional genomics of coronary artery dis-
ease remains unknown. Whole transcriptome studies 
using RNA-Seq can simultaneously comprehensively 
profile both coding and non-coding genes and transcripts 
associated with disease status, providing new knowledge 
and functional biological insights into human diseases.
We first systematically characterized expression pat-
terns of coding mRNAs and non-coding lincRNAs in 
whole blood through a high-coverage of RNA-sequenc-
ing experiment (one sample per lane). Much more 
highly-expressed coding genes are identified comparing 
to lincRNAs in whole blood, which is consistent with a 
previous report [32]. When compared to 16 other human 
tissues, a larger percentage of lincRNAs versus coding 
genes are expressed especially in whole blood, indicat-
ing that lincRNAs might be more tissue/cell-type specific 
compared to coding genes. Further studies with a greater 
diversity of tissue/cell data generated from the same 
research participants are needed to confirm this finding.
We identified coding and non-coding gene expres-
sion signatures associated with prior early MI, and a 
few expression signatures were also discovered for high 
CAC, a noninvasive measure of coronary atheroscle-
rosis, which precedes most cases of MI [3, 4]. Of note, 
APOD, encoding a component of high density lipopro-
tein, was expressed significantly lower in both early MI 
(FDR = 0.007) and in high CAC (FDR = 0.01) compared 
with controls, respectively. Altered expression of APOD 
was not reported to be significantly associated with cor-
onary heart disease in our prior FHS investigation [35], 
but the cases were not of early onset and only half of the 
cases had prior MI. Furthermore, a prior separate FHS 
investigation found that protein level of APOD is also 
decreased in MI new-onset patients compared to con-
trols [36], providing orthogonal evidence for APOD as an 
attractive novel candidate for clinical and subclinical ath-
erosclerosis. Tsukamoto et al. reported altered response 
to myocardial infarction in Apod knockout mice [37], 
revealing APOD as a cardioprotective gene using a mouse 
model of lethal atherosclerotic coronary artery disease. 
In addition, high levels of APOD protein in humans are 
associated with protective inflammatory levels and fatty 
liver in initial human studies [38, 39]. Further investiga-
tion of APOD in mouse models and larger human studies 
will be needed for experimental validation of this mecha-
nism, and to allow investigation of underlying mecha-
nisms related to atherosclerotic coronary artery disease.
In addition, despite our relatively modest sample size, 
we identified 71 gene expression signatures for MI and 
CAC in whole blood. Pathway analysis for these genes 
highlighted immune response, lipid metabolic pro-
cesses, and interferon regulatory factor as potential 
pathways involved in disease progress/pathogenesis, 
consistent with the known pathophysiology of coronary 
artery disease.
Fig. 3 GSEA result of 70 MI genes (21 upregulated, and 49 
down‑regulated in Table 2), of which 66 unique genes found in Exon 
array platform. The list of 17,873 coding genes ranked by t value 
of comparing early MI with control on Affymetrix Exon array data 
(N = 193 samples). Normalized Enrichment Score (NES) = −2.14, 
Nominal p‑value = 0 and FDR q‑value =0
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Only a few lincRNA expression signatures were found 
to be associated in either MI or CAC, which might be 
due to a relatively small sample size and much lower 
abundance of lincRNAs in human tissues. Because we 
undertook deep sequencing coverage, we were able to 
identify many lincRNA specifically expressed in blood 
that are likely not reliably detected in lower coverage 
RNA-Seq experiments. The lincRNA RP11-245 J9.5 
associated with CAC is of interest. It expressed high in 
peripheral blood and log2FC = − 0.6 (Fig. 2d). This gene 
is also known as PSMD6-AS2, a gene that could dis-
rupt expression of a proteasome subunit. This gene was 
identified as differentially expressed in a study of ath-
erosclerotic macrophages [40]. Another proteasomal 
subunit, PSMC3 mutation is associated with subcuta-
neous calcifications [41], indicating that this lincRNA 
RP11-245 J9.5 might be involved in atherosclerosis by 
regulating several proteasome subunits. However, fur-
ther replication of its association with CAC in inde-
pendent studies is needed to warrant future experiment 
mechanism studies of this lincRNA and identification 
of its functional targets. LincRNA may act as key tran-
scriptional regulators in different stages of biological 
systems, from chromatin regulation to transcription 
regulation [22]. Future studies are warranted to explore 
the relationship between these lincRNA signatures and 
their regulated mRNA targets and specific biological 
process in atherosclerosis, and the implications for new 
therapeutic targets for treatment and prevention of 
clinical MI and subclinical atherosclerosis.
Pathway enrichment analysis identified interesting 
results including a pathway/gene set called “STAT3_TAR-
GETS_DN”. Signal transducer and activator of transcrip-
tion 3 (STAT3) protein has been linked to cardiovascular 
disease through multiple pathways in experimental and 
animal studies [42, 43]. STAT3 is a key regulator of cell-
to-cell communication in the heart, modulates prolif-
eration, differentiation, survival, oxidative stress, and/or 
metabolism in cardiomyocytes, fibroblasts, endothelial 
cells, progenitor cells, and various inflammatory cells 
[44]. It has been well documented that monocytes and 
macrophages produce inflammatory cytokines to repair 
the injury during myocardial infarction and hypertrophy 
[45]. The early activation of STAT3 during diseased stage 
could be the protective response of system to reduce the 
cardiac death and remodeling through transcription fac-
tor STAT3 binds to promoter region of cardio-protective 
genes in nucleus [43].
In our study, we have adjusted for well-known risk fac-
tors for MI and subclinical atherosclerosis. Future studies 
in larger cohorts with clinically apparent coronary heart 
disease or subclinical atherosclerosis will allow explora-
tion of the role of specific risk factors in the progression 
of subclinical atherosclerosis to clinical atherosclerosis 
at the molecular level. In addition to our modest sam-
ple size, the major limitation of our study is the use of 
whole blood RNA, which includes heterogeneity of leu-
kocyte cell types, although we adjusted for differences of 
cell types in our study. Future RNA-Seq experiments in 
affected tissues/cells such as atherosclerotic aortic root 
cells and coronary artery endothelial cells are warranted.
While we acknowledge there are limitations to our 
pilot study, we believe we have identified several lessons 
for future applications of whole blood RNA sequenc-
ing for discovery of coronary atherosclerosis genes. 
Among the limitations, RNA-Seq experiments are still 
costly, and as with our study, the resulting relatively 
small sample size of these experiments may continue to 
limit statistical power to study rare RNA species such 
as lincRNAs that require deep coverage sequencing. 
Further, non-strand-specific RNA-Seq protocol limits 
accurate discovery of antisense transcripts and might 
lead to bias for quantifying genes that overlap with 
anti-sense transcripts. Finally, unmeasured confound-
ers may affect results of association studies. Neverthe-
less, we conclude that blood RNA sequencing analysis 
is feasible and may detect a much fuller and informa-
tive spectrum of gene expression than is seen on gene 
chip arrays, although careful RNA extraction and high 
resolution sequencing will be required for early studies.
Conclusion
In summary, we identified significant MI-specific 
expression signatures, with eight genes (15%) supported 
in an independent cohort with RNA-Seq data. Of note, 
APOD, encoding a component of high-density lipopro-
tein, was significantly downregulated in both early MI 
and in high CAC compared with controls, indicating a 
novel candidate target for the treatment and prevention 
of atherosclerotic disease. Our findings provide insights 
into mechanisms through which transcriptome-level 
variation may influence the development of subclinical 
coronary atherosclerosis and, ultimately, clinical MI.
Supplementary Information
The online version contains supplementary material available at https ://doi.
org/10.1186/s1292 0‑020‑00838 ‑2.
Additional file 1. Supplementary Material including Methods, Figures 
and Tables.
Abbreviations
CAC : Coronary artery calcification; CPM: Counts per million mapped reads; 
DEGs: Differentially expressed genes; FDR: False discovery rate; FHS: Framing‑
ham Heart Study; FPKM: Fragments per kilobase of transcript per million 
mapped reads; GSEA: Gene set enrichment analysis; GWAS: Genome‑wide 
Page 15 of 17Zhang et al. BMC Med Genomics           (2021) 14:45  
association studies; lincRNAs: Long intergenic noncoding RNAs; MI: Myocardial 
infarction; PCA: Principle component analysis; RIN: RNA integrity number.
Acknowledgments
This research was conducted in part using data and resources from the 
Framingham Heart Study of the National Heart Lung and Blood Institute 
(NHLBI) of the National Institutes of Health and Boston University School of 
Medicine. The analyses reflect intellectual input and resource development 
from the Framingham Heart Study investigators participating in the SNP 
Health Association Resource (SHARe) project and in the Systems Approach to 
Biomarker Research in Cardiovascular Disease (SABRe) project.
This study utilized the high‑performance computational capabilities of the 
Biowulf Linux cluster at the National Institutes of Health, Bethesda, Md. (http://
biowu lf.nih.gov).
Preliminary findings from this study were presented in the American Heart 
Association Scientific Session as an Abstract (Circulation. 2015 Nov 10;132 
(suppl_3):A15476), which can be accessed by following the link: https ://www.
ahajo urnal s.org/doi/10.1161/circ.132.suppl _3.15476 
Authors’ contributions
X.Z. and C.J.O. designed the study. X.Z. developed the method, performed the 
analyses, and wrote the manuscript. C.J.O. conceived and coordinated the pro‑
ject, and wrote the manuscript. S.H. generated the clinical characteristics data 
of the 198 FHS Offspring participants included in this study. Y.W., Y.Y. and J.Z. 
performed the RNA Sequencing experiment for the FHS cohort. J.R., M.G., D.B., 
J.M., and M.K. performed independent replication of our MI expression signa‑
tures using Illumina RNA‑Seq in the Rotterdam Study Cohort. D.L. and A.D.J. 
provided key input and revised the manuscript. D.L. provided the normalized 
expression Exon array data for the FHS cohort. J.Z., A.D.J., and D.L. reviewed the 
manuscript. All authors read and approved the final manuscript.
Funding
The Framingham Heart Study is funded by the National Institutes of Health 
contract N01‑HC‑25195; this work was also supported by the National Heart, 
Lung and Blood Institute, Division of Intramural Research. Funding agencies 
played no role in study design, data collection, analysis, interpretation of 
results, or writing the manuscript.
Availability of data and materials
The expression levels for these 25,593 coding genes and 8,267 lincRNAs were 
deposited in the NCBI database of genotypes and phenotypes (dbGaP) under 
the Dataset Accession ID (phs000007).
Ethics approval and consent to participate
Study protocol was approved by the Framingham Heart Study Ethics Commit‑




The authors declare no competing financial interests.The views expressed in 
this manuscript are those of the authors and do not necessarily represent the 
views of the National Heart, Lung, and Blood Institute; the National Institutes 
of Health; or the U.S. Department of Health and Human Services.This work 
was performed within the framework of the Biobank‑Based Integrative Omics 
Studies (BIOS) Consortium funded by BBMRI‑NL, a research infrastructure 
financed by the Dutch government (NWO 184.021.007). The Rotterdam study 
is funded by the Erasmus Medical Center and Erasmus University, Rotterdam, 
Netherlands Organization for the Health Research and development (ZonMw), 
the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Educa‑
tion, Culture and Science, the ministry for Health, Welfare and Sports, the 
European Commission (DG XII), and the Municipality of Rotterdam.
Author details
1 Division of Intramural Research, National Heart, Lung and Blood Institute, 
Bethesda, MD, USA. 2 The National Heart, Lung and Blood Institute’s Framing‑
ham Heart Study, Framingham, MA, USA. 3 Department of Medicine (Biomedi‑
cal Genetics), Boston University School of Medicine, 72 East Concord Street, 
Boston, MA 02118‑2526, USA. 4 Department of Biostatistics, Boston University 
School of Public Health, Boston, MA, USA. 5 Department of Internal Medicine, 
Erasmus Medical Center, Rotterdam, the Netherlands. 6 DNA Sequencing 
and Genomics Core, National Heart, Lung and Blood Institute, Bethesda, MD, 
USA. 7 Department of Epidemiology, Erasmus Medical Center, Rotterdam, 
the Netherlands. 8 Department of Radiology and Nuclear Medicine, Erasmus 
Medical Center, Rotterdam, the Netherlands. 9 Cardiology Section, Veteran’s 
Administration Boston Healthcare System, Boston, USA. 
Received: 11 February 2020   Accepted: 29 November 2020
References
 1. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic 
susceptibility to death from coronary heart disease in a study of twins. N 
Engl J Med. 1994;330:1041–6.
 2. Lloyd‑Jones DM, Nam BH, D’Agostino RB Sr, Levy D, Murabito JM, Wang TJ, 
Wilson PW, O’Donnell CJ. Parental cardiovascular disease as a risk factor 
for cardiovascular disease in middle‑aged adults: a prospective study of 
parents and offspring. JAMA. 2004;291:2204–11.
 3. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpat‑
rick LA, Schwartz RS. Arterial calcification and not lumen stenosis is highly 
correlated with atherosclerotic plaque burden in humans: a histologic 
study of 723 coronary artery segments using nondecalcifying methodol‑
ogy. J Am Coll Cardiol. 1998;31:126–33.
 4. Sharma RK, Voelker DJ, Singh VN, Pahuja D, Nash T, Reddy HK. Cardiac risk 
stratification: role of the coronary calcium score. Vasc Health Risk Manag. 
2010;6:603–11.
 5. Khera A, Budoff MJ, O’Donnell CJ, Ayers CA, Locke J, de Lemos JA, Mas‑
saro JM, McClelland RL, Taylor A, Levine BD. Astronaut cardiovascular 
health and risk modification (astro‑charm) coronary calcium atheroscle‑
rotic cardiovascular disease risk calculator. Circulation. 2018;138:1819–27.
 6. Hoffmann U, Massaro JM, D’Agostino RB Sr, Kathiresan S, Fox CS, 
O’Donnell CJ. Cardiovascular event prediction and risk reclassification by 
coronary, aortic, and valvular calcification in the Framingham heart study. 
J Am Heart Assoc. 2016;5:e003144.
 7. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss 
M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, 
Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, 
Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt 
SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, 
Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan 
A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari 
NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom 
AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, 
Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren 
C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, 
Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander 
K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, 
Martinelli N, PP MK, Meisinger C, Meitinger T, Melander O, Merlini PA, 
Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru 
K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson 
CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, 
Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, 
Schafer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick 
DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, 
Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, 
Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij 
AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg 
C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, 
Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, 
Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts 
R, Thorsteinsdottir U, O’Donnell CJ, McPherson R, Erdmann J, Samani NJ. 
Large‑scale association analysis identifies 13 new susceptibility loci for 
coronary artery disease. Nat Genet. 2011;43:333–8.
 8. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen 
D, Kyriakou T, Nelson CP, Hopewell JC, Webb TR, Zeng L, Dehghan A, 
Alver M, Armasu SM, Auro K, Bjonnes A, Chasman DI, Chen S, Ford I, 
Franceschini N, Gieger C, Grace C, Gustafsson S, Huang J, Hwang SJ, Kim 
YK, Kleber ME, Lau KW, Lu X, Lu Y, Lyytikainen LP, Mihailov E, Morrison 
Page 16 of 17Zhang et al. BMC Med Genomics           (2021) 14:45 
AC, Pervjakova N, Qu L, Rose LM, Salfati E, Saxena R, Scholz M, Smith AV, 
Tikkanen E, Uitterlinden A, Yang X, Zhang W, Zhao W, de Andrade M, 
de Vries PS, van Zuydam NR, Anand SS, Bertram L, Beutner F, Dedous‑
sis G, Frossard P, Gauguier D, Goodall AH, Gottesman O, Haber M, Han 
BG, Huang J, Jalilzadeh S, Kessler T, Konig IR, Lannfelt L, Lieb W, Lind L, 
Lindgren CM, Lokki ML, Magnusson PK, Mallick NH, Mehra N, Meitinger 
T, Memon FU, Morris AP, Nieminen MS, Pedersen NL, Peters A, Rallidis LS, 
Rasheed A, Samuel M, Shah SH, Sinisalo J, Stirrups KE, Trompet S, Wang L, 
Zaman KS, Ardissino D, Boerwinkle E, Borecki IB, Bottinger EP, Buring JE, 
Chambers JC, Collins R, Cupples LA, Danesh J, Demuth I, Elosua R, Epstein 
SE, Esko T, Feitosa MF, Franco OH, Franzosi MG, Granger CB, Gu D, Gudna‑
son V, Hall AS, Hamsten A, Harris TB, Hazen SL, Hengstenberg C, Hofman 
A, Ingelsson E, Iribarren C, Jukema JW, Karhunen PJ, Kim BJ, Kooner JS, 
Kullo IJ, Lehtimaki T, RJF L, Melander O, Metspalu A, Marz W, Palmer CN, 
Perola M, Quertermous T, Rader DJ, Ridker PM, Ripatti S, Roberts R, Salo‑
maa V, Sanghera DK, Schwartz SM, Seedorf U, Stewart AF, Stott DJ, Thiery 
J, Zalloua PA, O’Donnell CJ, Reilly MP, Assimes TL, Thompson JR, Erdmann 
J, Clarke R, Watkins H, Kathiresan S, McPherson R, Deloukas P, Schun‑
kert H, Samani NJ, Farrall M. A comprehensive 1,000 genomes‑based 
genome‑wide association meta‑analysis of coronary artery disease. Nat 
Genet. 2015;47:1121–30.
 9. O’Donnell CJ, Kavousi M, Smith AV, Kardia SL, Feitosa MF, Hwang SJ, Sun 
YV, Province MA, Aspelund T, Dehghan A, Hoffmann U, Bielak LF, Zhang Q, 
Eiriksdottir G, van Duijn CM, Fox CS, de Andrade M, Kraja AT, Sigurdsson S, 
Elias‑Smale SE, Murabito JM, Launer LJ, van der Lugt A, Kathiresan S, Kres‑
tin GP, Herrington DM, Howard TD, Liu Y, Post W, Mitchell BD, O’Connell 
JR, Shen H, Shuldiner AR, Altshuler D, Elosua R, Salomaa V, Schwartz SM, 
Siscovick DS, Voight BF, Bis JC, Glazer NL, Psaty BM, Boerwinkle E, Heiss 
G, Blankenberg S, Zeller T, Wild PS, Schnabel RB, Schillert A, Ziegler A, 
Munzel TF, White CC, Rotter JI, Nalls M, Oudkerk M, Johnson AD, Newman 
AB, Uitterlinden AG, Massaro JM, Cunningham J, Harris TB, Hofman A, 
Peyser PA, Borecki IB, Cupples LA, Gudnason V, Witteman JC. Genome‑
wide association study for coronary artery calcification with follow‑up in 
myocardial infarction. Circulation. 2011;124:2855–64.
 10. Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P, 
Kiezun A, Farrall M, Goel A, Zuk O, Guella I, Asselta R, Lange LA, Peloso GM, 
Auer PL, Girelli D, Martinelli N, Farlow DN, MA DP, Roberts R, Stewart AF, 
Saleheen D, Danesh J, Epstein SE, Sivapalaratnam S, Hovingh GK, Kaste‑
lein JJ, Samani NJ, Schunkert H, Erdmann J, Shah SH, Kraus WE, Davies R, 
Nikpay M, Johansen CT, Wang J, Hegele RA, Hechter E, Marz W, Kleber ME, 
Huang J, Johnson AD, Li M, Burke GL, Gross M, Liu Y, Assimes TL, Heiss G, 
Lange EM, Folsom AR, Taylor HA, Olivieri O, Hamsten A, Clarke R, Reilly DF, 
Yin W, Rivas MA, Donnelly P, Rossouw JE, Psaty BM, Herrington DM, Wilson 
JG, Rich SS, Bamshad MJ, Tracy RP, Cupples LA, Rader DJ, Reilly MP, Spertus 
JA, Cresci S, Hartiala J, Tang WH, Hazen SL, Allayee H, Reiner AP, Carlson 
CS, Kooperberg C, Jackson RD, Boerwinkle E, Lander ES, Schwartz SM, 
Siscovick DS, McPherson R, Tybjaerg‑Hansen A, Abecasis GR, Watkins H, 
Nickerson DA, Ardissino D, Sunyaev SR, O’Donnell CJ, Altshuler D, Gabriel 
S, Kathiresan S. Exome sequencing identifies rare ldlr and apoa5 alleles 
conferring risk for myocardial infarction. Nature. 2015;518:102–6.
 11. Natarajan P, Bis JC, Bielak LF, Cox AJ, Dorr M, Feitosa MF, Franceschini N, 
Guo X, Hwang SJ, Isaacs A, Jhun MA, Kavousi M, Li‑Gao R, Lyytikainen 
LP, Marioni RE, Schminke U, Stitziel NO, Tada H, van Setten J, Smith AV, 
Vojinovic D, Yanek LR, Yao J, Yerges‑Armstrong LM, Amin N, Baber U, 
Borecki IB, Carr JJ, Chen YI, Cupples LA, de Jong PA, de Koning H, de Vos 
BD, Demirkan A, Fuster V, Franco OH, Goodarzi MO, Harris TB, Heckbert SR, 
Heiss G, Hoffmann U, Hofman A, Isgum I, Jukema JW, Kahonen M, Kardia 
SL, Kral BG, Launer LJ, Massaro J, Mehran R, Mitchell BD, Mosley TH Jr, de 
Mutsert R, Newman AB, Nguyen KD, North KE, O’Connell JR, Oudkerk 
M, Pankow JS, Peloso GM, Post W, Province MA, Raffield LM, Raitakari 
OT, Reilly DF, Rivadeneira F, Rosendaal F, Sartori S, Taylor KD, Teumer A, 
Trompet S, Turner ST, Uitterlinden AG, Vaidya D, van der Lugt A, Volker U, 
Wardlaw JM, Wassel CL, Weiss S, Wojczynski MK, Becker DM, Becker LC, 
Boerwinkle E, Bowden DW, Deary IJ, Dehghan A, Felix SB, Gudnason V, 
Lehtimaki T, Mathias R, Mook‑Kanamori DO, Psaty BM, Rader DJ, Rotter JI, 
Wilson JG, van Duijn CM, Volzke H, Kathiresan S, Peyser PA, O’Donnell CJ, 
Consortium C. Multiethnic exome‑wide association study of subclinical 
atherosclerosis. Circ Cardiovasc Genet. 2016;9:511–20.
 12. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a 
community: the Framingham study. Ann N Y Acad Sci. 1963;107:539–56.
 13. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An inves‑
tigation of coronary heart disease in families. The Framingham offspring 
study. Am J Epidemiol. 1979;110:281–90.
 14. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The 
Framingham offspring study. Design and preliminary data. Prev Med. 
1975;4:518–25.
 15. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, 
D’Agostino RB Sr, Fox CS, Larson MG, Murabito JM, O’Donnell CJ, Vasan 
RS, Wolf PA, Levy D. The third generation cohort of the national heart, 
lung, and blood institute’s Framingham heart study: design, recruit‑
ment, and initial examination. Am J Epidemiol. 2007;165:1328–35.
 16. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. Tophat2: 
accurate alignment of transcriptomes in the presence of insertions, 
deletions and gene fusions. Genome Biol. 2013;14:R36.
 17. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho‑Silva D, 
Clapham P, Coates G, Fitzgerald S, Gil L, Giron CG, Gordon L, Hourlier 
T, Hunt S, Johnson N, Juettemann T, Kahari AK, Keenan S, Kulesha 
E, Martin FJ, Maurel T, McLaren WM, Murphy DN, Nag R, Overduin B, 
Pignatelli M, Pritchard B, Pritchard E, Riat HS, Ruffier M, Sheppard D, 
Taylor K, Thormann A, Trevanion SJ, Vullo A, Wilder SP, Wilson M, Zadissa 
A, Aken BL, Birney E, Cunningham F, Harrow J, Herrero J, Hubbard TJ, 
Kinsella R, Muffato M, Parker A, Spudich G, Yates A, Zerbino DR, Searle 
SM. Ensembl 2014. Nucleic Acids Res. 2014;42:D749–55.
 18. Roberts A, Trapnell C, Donaghey J, Rinn JL, Pachter L. Improving rna‑
seq expression estimates by correcting for fragment bias. Genome Biol. 
2011;12:R22.
 19. Robinson MD, McCarthy DJ, Smyth GK. Edger: a bioconductor package 
for differential expression analysis of digital gene expression data. 
Bioinformatics. 2010;26:139–40.
 20. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, 
Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 
2011;29:24–6.
 21. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative genomics viewer 
(igv): high‑performance genomics data visualization and exploration. 
Brief Bioinform. 2013;14:178–92.
 22. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, 
Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, 
Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. The 
landscape of long noncoding rnas in the human transcriptome. Nat 
Genet. 2015;47:199–208.
 23. Ranzani V, Rossetti G, Panzeri I, Arrigoni A, Bonnal RJ, Curti S, Gruarin P, 
Provasi E, Sugliano E, Marconi M, De Francesco R, Geginat J, Bodega B, 
Abrignani S, Pagani M. The long intergenic noncoding rna landscape of 
human lymphocytes highlights the regulation of t cell differentiation 
by linc‑maf‑4. Nat Immunol. 2015;16:318–25.
 24. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for 
removing batch effects and other unwanted variation in high‑through‑
put experiments. Bioinformatics. 2012;28:882–3.
 25. Love MI, Huber W, Anders S. Moderated estimation of fold change and 
dispersion for rna‑seq data with deseq2. Genome Biol. 2014;15:550.
 26. Huang d W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: 
paths toward the comprehensive functional analysis of large gene lists. 
Nucleic Acids Res. 2009;37:1–13.
 27. Huang d W, Sherman BT, Lempicki RA. Systematic and integrative 
analysis of large gene lists using David bioinformatics resources. Nat 
Protoc. 2009;4:44–57.
 28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette 
MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene 
set enrichment analysis: a knowledge‑based approach for interpret‑
ing genome‑wide expression profiles. Proc Natl Acad Sci U S A. 
2005;102:15545–50.
 29. Wang L, Wang S, Li W. Rseqc: quality control of rna‑seq experiments. 
Bioinformatics. 2012;28:2184–5.
 30. Raghavachari N, Barb J, Yang Y, Liu P, Woodhouse K, Levy D, O’Donnell 
CJ, Munson PJ, Kato GJ. A systematic comparison and evaluation of 
high density exon arrays and rna‑seq technology used to unravel the 
Page 17 of 17Zhang et al. BMC Med Genomics           (2021) 14:45  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
peripheral blood transcriptome of sickle cell disease. BMC Med Genet. 
2012;5:28.
 31. Zhernakova DV, Deelen P, Vermaat M, van Iterson M, van Galen M, 
Arindrarto W, van’t Hof P, Mei H, van Dijk F, Westra HJ, Bonder MJ, van 
Rooij J, Verkerk M, Jhamai PM, Moed M, Kielbasa SM, Bot J, Nooren I, 
Pool R, van Dongen J, Hottenga JJ, Stehouwer CD, van der Kallen CJ, 
Schalkwijk CG, Zhernakova A, Li Y, Tigchelaar EF, de Klein N, Beekman 
M, Deelen J, van Heemst D, van den Berg LH, Hofman A, Uitterlinden 
AG, van Greevenbroek MM, Veldink JH, Boomsma DI, van Duijn CM, 
Wijmenga C, Slagboom PE, Swertz MA, Isaacs A, van Meurs JB, Jansen 
R, Heijmans BT, t Hoen PA, Franke L. Identification of context‑depend‑
ent expression quantitative trait loci in whole blood. Nat Genet. 
2017;49:139–45.
 32. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon‑Vega B, Regev A, Rinn JL. 
Integrative annotation of human large intergenic noncoding rnas reveals 
global properties and specific subclasses. Genes Dev. 2011;25:1915–27.
 33. Farrell CM, O’Leary NA, Harte RA, Loveland JE, Wilming LG, Wallin C, 
Diekhans M, Barrell D, Searle SM, Aken B, Hiatt SM, Frankish A, Suner MM, 
Rajput B, Steward CA, Brown GR, Bennett R, Murphy M, Wu W, Kay MP, 
Hart J, Rajan J, Weber J, Snow C, Riddick LD, Hunt T, Webb D, Thomas M, 
Tamez P, Rangwala SH, KM MG, Pujar S, Shkeda A, Mudge JM, Gonzalez 
JM, Gilbert JG, Trevanion SJ, Baertsch R, Harrow JL, Hubbard T, Ostell JM, 
Haussler D, Pruitt KD. Current status and new features of the consensus 
coding sequence database. Nucleic Acids Res. 2014;42:D865–72.
 34. Cunningham F, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho‑
Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Giron CG, Gordon L, Hour‑
lier T, Hunt SE, Janacek SH, Johnson N, Juettemann T, Kahari AK, Keenan S, 
Martin FJ, Maurel T, McLaren W, Murphy DN, Nag R, Overduin B, Parker A, 
Patricio M, Perry E, Pignatelli M, Riat HS, Sheppard D, Taylor K, Thormann 
A, Vullo A, Wilder SP, Zadissa A, Aken BL, Birney E, Harrow J, Kinsella R, 
Muffato M, Ruffier M, Searle SM, Spudich G, Trevanion SJ, Yates A, Zerbino 
DR, Flicek P. Ensembl 2015. Nucleic Acids Res. 2015;43:D662–9.
 35. Joehanes R, Ying S, Huan T, Johnson AD, Raghavachari N, Wang R, Liu 
P, Woodhouse KA, Sen SK, Tanriverdi K, Courchesne P, Freedman JE, 
O’Donnell CJ, Levy D, Munson PJ. Gene expression signatures of coronary 
heart disease. Arterioscler Thromb Vasc Biol. 2013;33:1418–26.
 36. Yin X, Subramanian S, Hwang SJ, O’Donnell CJ, Fox CS, Courchesne 
P, Muntendam P, Gordon N, Adourian A, Juhasz P, Larson MG, Levy D. 
Protein biomarkers of new‑onset cardiovascular disease: prospective 
study from the systems approach to biomarker research in cardiovascular 
disease initiative. Arterioscler Thromb Vasc Biol. 2014;34:939–45.
 37. Tsukamoto K, Mani DR, Shi J, Zhang S, Haagensen DE, Otsuka F, Guan J, 
Smith JD, Weng W, Liao R, Kolodgie FD, Virmani R, Krieger M. Identification 
of apolipoprotein d as a cardioprotective gene using a mouse model of 
lethal atherosclerotic coronary artery disease. Proc Natl Acad Sci U S A. 
2013;110:17023–8.
 38. Desmarais F, Bergeron KF, Lacaille M, Lemieux I, Bergeron J, Biron S, Ras‑
sart E, Joanisse DR, Mauriege P, Mounier C. High apod protein level in the 
round ligament fat depot of severely obese women is associated with an 
improved inflammatory profile. Endocrine. 2018;61:248–57.
 39. Labrie M, Lalonde S, Najyb O, Thiery M, Daneault C, Des Rosiers C, Rassart 
E, Mounier C. Apolipoprotein d transgenic mice develop hepatic steatosis 
through activation of ppargamma and fatty acid uptake. PLoS One. 
2015;10:e0130230.
 40. Wang W, Zhang K, Zhang H, Li M, Zhao Y, Wang B, Xin W, Yang W, 
Zhang J, Yue S, Yang X. Underlying genes involved in atherosclerotic 
macrophages: insights from microarray data mining. Med Sci Monit. 
2019;25:9949–62.
 41. Kroll‑Hermi A, Ebstein F, Stoetzel C, Geoffroy V, Schaefer E, Scheidecker S, 
Bar S, Takamiya M, Kawakami K, Zieba BA, Studer F, Pelletier V, Eyermann 
C, Speeg‑Schatz C, Laugel V, Lipsker D, Sandron F, McGinn S, Boland A, 
Deleuze JF, Kuhn L, Chicher J, Hammann P, Friant S, Etard C, Kruger E, 
Muller J, Strahle U, Dollfus H. Proteasome subunit psmc3 variants cause 
neurosensory syndrome combining deafness and cataract due to proteo‑
toxic stress. EMBO Mol Med. 2020;12:e11861.
 42. Zhang L, Kao WH, Berthier‑Schaad Y, Liu Y, Plantinga L, Jaar BG, Fink N, 
Powe N, Klag MJ, Smith MW, Coresh J. Haplotype of signal transducer 
and activator of transcription 3 gene predicts cardiovascular disease in 
dialysis patients. J Am Soc Nephrol. 2006;17:2285–92.
 43. Kishore R, Verma SK. Roles of stats signaling in cardiovascular diseases. 
JAKSTAT. 2012;1:118–24.
 44. Haghikia A, Ricke‑Hoch M, Stapel B, Gorst I, Hilfiker‑Kleiner D. Stat3, a 
key regulator of cell‑to‑cell communication in the heart. Cardiovasc Res. 
2014;102:281–9.
 45. Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD, Baker KM. 
Molecular mechanisms of angiotensin ii in modulating cardiac function: 
Intracardiac effects and signal transduction pathways. J Mol Cell Cardiol. 
1997;29:2893–902.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
